… evaluating the combination of AZD9291 and the MEK inhibitor … to prevent or treat drug
resistance in EGFR-mutant lung cancer … point toward improving EGFR TKI combination strategies. …

… resistant EGFR-mutant NSCLC cells (B). The red arrows indicate the changes caused by
osimertinib (A) or the combination … and even preventing the emergence of acquired resistance, …

… models of EGFR mutant lung cancer, acquired resistance to … Combined treatment with
osimertinib and the MEK inhibitor selumetinib prevented the emergence of cancer cell resistance …

… in EGFR-mutant lung cancer therapy is the development of acquired … for combination therapy
for EGFR-mutant lung cancer. … However, G was unable to prevent tumor regrowth after 4–5 …

… and preventing the rise of the dominant resistance clone. Drug … EGFR-mutant lung cancer
has been a model of drug … Resistance to the combination with trametinib may emerge due …

… of NF-κB rescues EGFR-mutant lung cancer cells from EGFR-TKI … combined treatment with
Akt and EGFR inhibitors in resistant … could delay the emergence of resistance in the T790M-…

… signaling in modulating development of acquired resistance to osimertinib and … inhibition
combined with osimertinib effectively inhibits the growth of osimertinib-resistant EGFR-mutant …

… For example, the emergence of a T790M gatekeeper … ~50% of EGFR mutant lung cancers
with acquired resistance to … drug resistance, and thus is a more effective combination strategy …

… be possible to acquire resistance to the 4D MLD combination therapy during a drug … of
EGFR mutant NSCLCs with MLD therapy effectively suppresses development of drug resistance, …

… In our cell models, development of EGFR TKI resistance under … resistance in EGFR-mutant
NSCLCs. These findings suggest that the combination of EGFR TKIs with FGFR1 inhibitors or …